Search

Your search keyword '"Johnston, D."' showing total 125 results
Start Over Author "Johnston, D." Publisher bmj
125 results on '"Johnston, D."'

1. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial)

Author

Ravikumar, R., Bartlett, D., Morton, D., Berkman, L., Bodenham-Chilton, H., Deeks, J. J., Handley, K., Magill, L., Hamilton, E., Hepburn, E., Hwang, M-J, Mirza, N., Wilkey, A., Magill, M. le Breuilly L., Wilcockson, A., Mehta, S., Burtenshaw, A., Hawkins, W., Voysey, M., Blazeby, J., Smith, I., Stocken, D., Abbott, S., Hwang, M., Karim, A., Luke, D. P., McArthur, D., Mistry, P., Richardson, J., Youssef, H., Ravi, K., Goodfellow, P. B., Gupta, R., Joy, H., Eardley, N., McFaul, C., Vimalachandran, D., Harmston, C., Froggatt, P., Krishnan, P., Pathare, S., Shanmugam, V., Yiannakou, Y. J., Fawole, A., Macklin, C., Mcenhill, J., Narula, H., Riad, T., Rose, A., Chambers, J., Ekere, C., Hough, M., Hull, J., Knight, H. P., Lamparelli, M. J., Lewis, M., Pulletz, M., Siddiqi, N., Stubbs, B., Subramanian, K., Swanton, R., Costigan, S., O'Connell, G., Patel, P. K., Ali, A., Ang, C., Chapman, M. A. S., Shariff, U., Thompson, C., Yates, A. Williamson J., Leinhardt, D. J., Simenacz, M., Harris, S., Loveless, P., Mohsen, Y., Myers, A., Prabhudesai, A., Vanagov, S., Aryal, K., Lal, R., Millican, D., Panagiotopopoulou, I., Shankar, K., Dube, M., Tansley, J., Hill, J., Addison, S., Church, R., Nath, J., Valap, S., Dhrampal, A., Nortje, J., Payne, J., Sargen, K., Speakman, C., Deloughry, J., Elkington, T., Dennis, R., Ghosh, S., Martin, J., Stoker, M., Akerman, N., Basheer, M., Drury, N., Parchment-Smith, C., Sandhu, R., Srinivasa, R., Varma, S., Walwyn, S., Syed, N., Bromilow, J., Colling, P., Reschreiter, H., Senapati, A., Howse, F., Tzouliadis, L., Bach, S., Brookes, A., Cagigas, C., Dimitriou, N., Fallis, S., Futaba, K., Hill, A., Izbal, A., Leong, K., Manji, M., Milns, P., Murray, A., Nicol, D., Pinkney, T., Ramcharam, S., Royle, T. J., Scarpinata, R., Smart, C., Smart, S., Suggett, N., Sutherland, S., Tam, Y. H. M., Torrance, A., Wall, M., Vakis, S., Bassuini, M., Garner, J., Maz, S., Mottahedeh, M., Smith, M., Withers, M., Krishnamourthy, R., Paraoan, M., Thomas, P., Chesshire, N., Davies, S., Gold, S., Hamzah, I., Hurst, N., Khoo, C. K., Kiani, S., Liptrot, S., Lund, J., Millard, C., Morris, C., Reynolds, J. R., Selvaraj, I., Simpson, A., Speake, W., Tou, S., Chambers, W., Gee, A. S., Grice, A., Johnston, D., Miller, Q., Pittman, J., Price, D., Telford, R., Barrow, E., Coldwell, C., Crighton, I., Raymond, T., Richmond, S., Cheetham, M., Kulemeka, G., Carraretto, M., Huddart, S., Kirk-Bayley, J., Moor, D., Scott, M., Asif, M., Awan, R., Bethune, R., Chadwick, M., Cook, T., Courtney, E., Dalton, S., Lim, A., Williamson, M. E. R., Wood, J., Scott, R., Branagan, G., Bellin, J., Browning, D., Bulso, V., Carter, N., Cruikshank, N., Gill, K., Hulme, N., Leno, E., Newbould, D., Thumbe, V., Sankar, K., Sivasubramaniam, S., Wakhle, R., Walton, R., Zulueta, L., Ahmad, S. M., Kaur, G., Longbottom, D., Nnaji, M., Ramamoorthy, A., Thomas, J., Botteril, I., Miskovic, D., Sagar, P. M., Bhuptani, S., Kennedy, R., Jenkins, I., Littler, S., Arnold, G., Buchanan, G., Con, A., Dawson, P., Lawrie, S., Lowe, J., Malhotra, S., Paraskeva, P., Richards, S., Sidhu, V., Ziprin, P., Kruchek, D., Kuttler, A., Mohammad, K., Nasser, T., Rehman, H., Siddiqui, K., Siddiqui, A., Sindhu, Q., Soliman, M., Solkar, M., Thota, S., Renehan, A., Selvasekar, C., Melsom, H., Agarwal, A. K., Borowski, D., Brohi, F., Garg, D., Gill, T., Mahadevan, V., Sharma, A., Tabaqchali, M. A., Alce, T., Navapurkar, A., Page, V., Stambach, T., Capozzi, P., Coe, P., Conroy, P., Duff, S., Grey, T., Hill, O., Nicholson, J., Nolan, D., Pollard, J., Ramesh, A., Sabar, M., Telford, K., Davies, D., Wilson, J., and Yates, D.

Subjects
Adult, Male, medicine.medical_specialty, Treatment outcome, Dexamethasone, law.invention, Eating, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, Preanesthetic Medication, 030202 anesthesiology, law, medicine, Humans, Postoperative Period, 030212 general & internal medicine, Young adult, Aged, Aged, 80 and over, business.industry, Research, Standard treatment, Recovery of Function, General Medicine, Length of Stay, Middle Aged, Surgery, Intestines, Treatment Outcome, Multicenter study, Anesthesia, Injections, Intravenous, Postoperative Nausea and Vomiting, Antiemetics, Female, medicine.symptom, business, Postoperative nausea and vomiting, medicine.drug
Abstract

Objectives To determine whether preoperative dexamethasone reduces postoperative vomiting in patients undergoing elective bowel surgery and whether it is associated with other measurable benefits during recovery from surgery, including quicker return to oral diet and reduced length of stay. Design Pragmatic two arm parallel group randomised trial with blinded postoperative care and outcome assessment. Setting 45 UK hospitals. Participants 1350 patients aged 18 or over undergoing elective open or laparoscopic bowel surgery for malignant or benign pathology. Interventions Addition of a single dose of 8 mg intravenous dexamethasone at induction of anaesthesia compared with standard care. Main outcome measures Primary outcome: reported vomiting within 24 hours reported by patient or clinician. Secondary outcomes: vomiting with 72 and 120 hours reported by patient or clinician; use of antiemetics and postoperative nausea and vomiting at 24, 72, and 120 hours rated by patient; fatigue and quality of life at 120 hours or discharge and at 30 days; time to return to fluid and food intake; length of hospital stay; adverse events. Results 1350 participants were recruited and randomly allocated to additional dexamethasone (n=674) or standard care (n=676) at induction of anaesthesia. Vomiting within 24 hours of surgery occurred in 172 (25.5%) participants in the dexamethasone arm and 223 (33.0%) allocated standard care (number needed to treat (NNT) 13, 95% confidence interval 5 to 22; P=0.003). Additional postoperative antiemetics were given (on demand) to 265 (39.3%) participants allocated dexamethasone and 351 (51.9%) allocated standard care (NNT 8, 5 to 11; P

Published
2017

2. Short stature in Noonan syndrome: response to growth hormone therapy

Author

Kirk, J, Betts, P, Butler, G, Donaldson, M, Dunger, D, Johnston, D, Kelnar, C, Price, D, Wilton, P, and Group, t. U.

Subjects
Male, medicine.medical_specialty, Pediatrics, Adolescent, medicine.medical_treatment, Growth hormone, Short stature, Internal medicine, Turner syndrome, medicine, Humans, Child, Growth Disorders, Chemotherapy, business.industry, Noonan Syndrome, medicine.disease, Long-Term Care, Osteochondrodysplasia, General and Acute Paediatrics, Body Height, Rheumatology, Surgery, Treatment Outcome, El Niño, Growth Hormone, Pediatrics, Perinatology and Child Health, Noonan syndrome, Female, medicine.symptom, business, Follow-Up Studies
Abstract

Background—Growth hormone (GH) has been used to promote growth in both the short and long term in a number of dysmorphic syndromes, including Turner syndrome. As this condition shares many clinical features with Noonan syndrome, it would seem logical to treat the latter group with GH. Aims—To assess the short and long term response to GH therapy in patients with Noonan syndrome. Methods—Analysis of patients with Noonan syndrome in the Pharmacia & Upjohn International Growth Study (this postmarketing database contains data on the majority of patients currently treated with GH in the UK). A questionnaire was also sent to participating clinicians. Results—Data on 66 patients (54 males) were available for study.At the start of GH therapy children were short, compared with both normal and Noonan children. During the first year of GH therapy height velocity increased from a mean of 4.9 to 7.2 cm per year. For patients treated long term with GH, mean height SDS increased from ˛2.9 pretreatment to ˛2.6 after one year and ˛2.3 after five years. Of the 10 patients at near final height, only one had a height above the 3rd centile for normal adults and above the mean for untreated Noonan patients. The mean increment in final height was 3.1 cm (range ˛1.1 to 6.5 cm). Conclusions—GH therapy in patients with Noonan syndrome will improve height velocity in the short term. Longer-term therapy results in a waning of eVect;initial indications are that final height is not improved substantially in most patients. (Arch Dis Child 2001;84:440‐443)

Published
2001

3. A decade of growth hormone treatment in girls with Turner syndrome in the UK

Author

Betts, P, Butler, G, Donaldson, M, Dunger, D, Johnston, D, Kelnar, C, Kirk, J, Price, D, Wilton, P, and the, U

Subjects
Adult, medicine.medical_specialty, Pediatrics, Gonad, Adolescent, Databases, Factual, Turner Syndrome, Growth hormone, Drug Administration Schedule, Cohort Studies, Growth velocity, Turner syndrome, medicine, Humans, Child, Medical Audit, business.industry, Body Weight, Final height, Age Factors, Original Articles, medicine.disease, Body Height, Surgery, Growth hormone treatment, Treatment Outcome, medicine.anatomical_structure, El Niño, Child, Preschool, Growth Hormone, Pediatrics, Perinatology and Child Health, Regression Analysis, Female, business, Cohort study
Abstract

Fifteen per cent of children treated with growth hormone (GH) are receiving treatment for Turner syndrome, but few results are available on final height in the UK. In this study, data were obtained from the UK KIGS database for 485 girls with Turner syndrome who were treated from 1986, allowing an audit of practice and outcome over 10 years. Over the decade, the mean age of starting growth hormone treatment fell from 10.4 to 8.5 years and the starting dose increased from 0.55 to 0.95 IU/kg/week. The frequency of injections increased from three to six or seven/week. Some girls received suboptimal doses, which also differed depending on whether they were based on weight or surface area. To assess what height gain might be expected at final height, all 52 girls who were prepubertal at the start of treatment, which continued for four years or more, and who had reached final height or had a growth velocity < 2 cm/year were selected. Their mean gain in final height was 5.2 cm and the GH dose was 0.78 IU/kg/week over 5.8 years. Final height gain correlated significantly with duration of treatment, total dose received, and first year response, which itself related to starting dose. This audit shows a changing pattern of treatment over the past decade, which in many instances has been inadequate. When treatment starts before puberty and continues through to final height, with a dose of 30 IU/m2/week in six or seven injections, a mean increase in final height of 5 cm or more would be expected.

Published
1999

4. PTU-149 Barrett’s Oesophagus Patients Attending Hospital: Baseline Clinical, Patient History and Quality of Life Data from Boss and Aspect

Author

Love, S, primary, Reilly, G, additional, Roberts, C, additional, Moayyedi, P, additional, Foy, C, additional, Stokes, C, additional, De Caestecker, J, additional, Attwood, S, additional, Watson, P, additional, Ang, Y, additional, Bhandari, P, additional, Old, O, additional, Hapeshi, J, additional, Penman, I, additional, Rodgers, C, additional, Edwards, C, additional, Monk, D, additional, Ragunath, K, additional, Morris, D, additional, Johnston, D, additional, Jankowski, J, additional, and Barr, H, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results